Drug recalls (page 6)
748 recalls.
- Albuterol Sulfate Inhalation Solution recall (Nephron SC, LLC)
DrugClass IIReported April 22, 2026 · Labelling: Illegible label - Fluocinonide recall (SUN PHARMACEUTICAL INDUSTRIES INC)
DrugClass IIReported April 22, 2026 · Failed Viscosity Specifications: Out of Specification results, above the specification limit, in viscosity, noted during stability testing. - Fluocinonide recall (SUN PHARMACEUTICAL INDUSTRIES INC)
DrugClass IIReported April 22, 2026 · Failed Viscosity Specifications: Out of Specification results, above the specification limit, in viscosity, noted during stability testing. - Fluocinonide recall (SUN PHARMACEUTICAL INDUSTRIES INC)
DrugClass IIReported April 22, 2026 · Failed Viscosity Specifications: Out of Specification results, above the specification limit, in viscosity, noted during stability testing. - Semaglutide-Glycine-Cyanocobalamin Injectable recall (PAYLESS COMPOUNDERS, LLC)
DrugClass IIReported April 22, 2026 · Lack of Assurance of Sterility - QC Quality Choice recall (Xiamen Kang Zhongyuan Biotechnology Co., Ltd.)
DrugClass IIReported April 22, 2026 · This recall is being initiated following FDA's recommendation based on certain observations noted during an August 15, 2025, inspection of the manufacturing... - QC Quality Choice recall (Xiamen Kang Zhongyuan Biotechnology Co., Ltd.)
DrugClass IIReported April 22, 2026 · This recall is being initiated following FDA's recommendation based on certain observations noted during an August 15, 2025, inspection of the manufacturing... - QC Quality Choice recall (Xiamen Kang Zhongyuan Biotechnology Co., Ltd.)
DrugClass IIReported April 22, 2026 · This recall is being initiated following FDA's recommendation based on certain observations noted during an August 15, 2025, inspection of the manufacturing... - QC Quality Choice recall (Xiamen Kang Zhongyuan Biotechnology Co., Ltd.)
DrugClass IIReported April 22, 2026 · This recall is being initiated following FDA's recommendation based on certain observations noted during an August 15, 2025, inspection of the manufacturing... - QC Quality Choice recall (Xiamen Kang Zhongyuan Biotechnology Co., Ltd.)
DrugClass IIReported April 22, 2026 · This recall is being initiated following FDA's recommendation based on certain observations noted during an August 15, 2025, inspection of the manufacturing... - QC Quality Choice recall (Xiamen Kang Zhongyuan Biotechnology Co., Ltd.)
DrugClass IIReported April 22, 2026 · This recall is being initiated following FDA's recommendation based on certain observations noted during an August 15, 2025, inspection of the manufacturing... - QC Quality Choice recall (Xiamen Kang Zhongyuan Biotechnology Co., Ltd.)
DrugClass IIReported April 22, 2026 · This recall is being initiated following FDA's recommendation based on certain observations noted during an August 15, 2025, inspection of the manufacturing... - MGC Health recall (Xiamen Kang Zhongyuan Biotechnology Co., Ltd.)
DrugClass IIReported April 22, 2026 · This recall is being initiated following FDA's recommendation based on certain observations noted during an August 15, 2025, inspection of the manufacturing... - MGC Health recall (Xiamen Kang Zhongyuan Biotechnology Co., Ltd.)
DrugClass IIReported April 22, 2026 · This recall is being initiated following FDA's recommendation based on certain observations noted during an August 15, 2025, inspection of the manufacturing... - MGC Health recall (Xiamen Kang Zhongyuan Biotechnology Co., Ltd.)
DrugClass IIReported April 22, 2026 · This recall is being initiated following FDA's recommendation based on certain observations noted during an August 15, 2025, inspection of the manufacturing... - Discount Drug Mart Food Market recall (Xiamen Kang Zhongyuan Biotechnology Co., Ltd.)
DrugClass IIReported April 22, 2026 · This recall is being initiated following FDA's recommendation based on certain observations noted during an August 15, 2025, inspection of the manufacturing... - Discount Drug Mart Food Market recall (Xiamen Kang Zhongyuan Biotechnology Co., Ltd.)
DrugClass IIReported April 22, 2026 · This recall is being initiated following FDA's recommendation based on certain observations noted during an August 15, 2025, inspection of the manufacturing... - caring mill recall (Xiamen Kang Zhongyuan Biotechnology Co., Ltd.)
DrugClass IIReported April 22, 2026 · This recall is being initiated following FDA's recommendation based on certain observations noted during an August 15, 2025, inspection of the manufacturing... - exchange select recall (Xiamen Kang Zhongyuan Biotechnology Co., Ltd.)
DrugClass IIReported April 22, 2026 · This recall is being initiated following FDA's recommendation based on certain observations noted during an August 15, 2025, inspection of the manufacturing... - exchange select recall (Xiamen Kang Zhongyuan Biotechnology Co., Ltd.)
DrugClass IIReported April 22, 2026 · This recall is being initiated following FDA's recommendation based on certain observations noted during an August 15, 2025, inspection of the manufacturing... - SLMD Benzoyl Peroxide Acne Lotion recall (Owen Biosciences Inc.)
DrugClass IIReported April 22, 2026 · Chemical contamination: Presence of benzene - SLMD BP Acne Spot Treatment recall (Owen Biosciences Inc.)
DrugClass IIReported April 22, 2026 · Chemical contamination: Presence of benzene - HydroPeptide CLEAR ALLIANCE SERUM recall (Owen Biosciences Inc.)
DrugClass IIReported April 22, 2026 · Chemical contamination: Presence of benzene - FHF Farmhouse Fresh recall (Owen Biosciences Inc.)
DrugClass IIReported April 22, 2026 · Chemical contamination: Presence of benzene - Cinacalcet Hydrochloride Tablets recall (Cipla USA, Inc.)
DrugClass IIReported April 22, 2026 · CGMP Deviations; presence N-Nitroso Cinacalcet above the acceptable daily intake limit - Cinacalcet Hydrochloride Tablets recall (Cipla USA, Inc.)
DrugClass IIReported April 22, 2026 · CGMP Deviations; presence N-Nitroso Cinacalcet above the acceptable daily intake limit - Cinacalcet Hydrochloride Tablets recall (Cipla USA, Inc.)
DrugClass IIReported April 22, 2026 · CGMP Deviations; presence N-Nitroso Cinacalcet above the acceptable daily intake limit - Clonidine Transdermal System recall (Teva Pharmaceuticals USA, Inc)
DrugClass IIReported April 15, 2026 · CGMP Deviations: use of an unapproved raw material - Clonidine Transdermal System recall (Teva Pharmaceuticals USA, Inc)
DrugClass IIReported April 15, 2026 · CGMP Deviations: use of an unapproved raw material - Clonidine Transdermal System recall (Teva Pharmaceuticals USA, Inc)
DrugClass IIReported April 15, 2026 · CGMP Deviations: use of an unapproved raw material - GE Healthcare Omnipaque recall (GE Healthcare Ireland Limited)
DrugClass IIReported April 15, 2026 · Presence of particulate matter - GE Healthcare Omnipaque recall (GE Healthcare Ireland Limited)
DrugClass IIReported April 15, 2026 · Presence of particulate matter - Isotretinoin Capsules recall (Teva Pharmaceuticals USA, Inc)
DrugClass IIReported April 15, 2026 · Superpotent and Subpotent - Isotretinoin Capsules recall (Teva Pharmaceuticals USA, Inc)
DrugClass IIReported April 15, 2026 · Superpotent and Subpotent - Xanax XR recall (Viatris, Inc.)
DrugClass IIReported April 15, 2026 · Failed Dissolution Specifications - Artificial Tears Lubricant Eye Drops recall (Preferred Pharmaceuticals, Inc.)
DrugClass IIReported April 15, 2026 · Lack of Assurance of Sterility - Vancomycin HCL recall (Fagron Compounding Services)
DrugClass IIReported April 15, 2026 · Lack of Assurance of Sterility; blue Break-Off-Part could detach from the administration port - Vancomycin HCI recall (Fagron Compounding Services)
DrugClass IIReported April 15, 2026 · Lack of Assurance of Sterility; blue Break-Off-Part could detach from the administration port - Vancomycin HCI recall (Fagron Compounding Services)
DrugClass IIReported April 15, 2026 · Lack of Assurance of Sterility; blue Break-Off-Part could detach from the administration port - norepinephrine Bitartrate recall (Fagron Compounding Services)
DrugClass IIReported April 15, 2026 · Lack of Assurance of Sterility; blue Break-Off-Part could detach from the administration port - norepinephrine Bitartrate recall (Fagron Compounding Services)
DrugClass IIReported April 15, 2026 · Lack of Assurance of Sterility; blue Break-Off-Part could detach from the administration port - 5% Dextrose Injection recall (Fresenius Kabi USA, LLC)
DrugClass IIReported April 15, 2026 · Lack of Assurance of Sterility - 5% Dextrose Injection recall (Fresenius Kabi USA, LLC)
DrugClass IIReported April 15, 2026 · Lack of Assurance of Sterility - 5% Dextrose Injection recall (Fresenius Kabi USA, LLC)
DrugClass IIReported April 15, 2026 · Lack of Assurance of Sterility - 0.9% Sodium Chloride Injection recall (Fresenius Kabi USA, LLC)
DrugClass IIReported April 15, 2026 · Lack of Assurance of Sterility - 0.9% Sodium Chloride Injection recall (Fresenius Kabi USA, LLC)
DrugClass IIReported April 15, 2026 · Lack of Assurance of Sterility - 0.9% Sodium Chloride Injection recall (Fresenius Kabi USA, LLC)
DrugClass IIReported April 15, 2026 · Lack of Assurance of Sterility - 0.9% Sodium Chloride Injection recall (Fresenius Kabi USA, LLC)
DrugClass IIReported April 15, 2026 · Lack of Assurance of Sterility - 0.9% Sodium Chloride Injection recall (Fresenius Kabi USA, LLC)
DrugClass IIReported April 15, 2026 · Lack of Assurance of Sterility - 0.9% Sodium Chloride Injection recall (Fresenius Kabi USA, LLC)
DrugClass IIReported April 15, 2026 · Lack of Assurance of Sterility - 0.9% Sodium Chloride Injection recall (Fresenius Kabi USA, LLC)
DrugClass IIReported April 15, 2026 · Lack of Assurance of Sterility - 0.9% Sodium Chloride Injection recall (Fresenius Kabi USA, LLC)
DrugClass IIReported April 15, 2026 · Lack of Assurance of Sterility - 0.9% Sodium Chloride Injection recall (Fresenius Kabi USA, LLC)
DrugClass IIReported April 15, 2026 · Lack of Assurance of Sterility - 0.9% Sodium Chloride Injection recall (Fresenius Kabi USA, LLC)
DrugClass IIReported April 15, 2026 · Lack of Assurance of Sterility - 0.45% Sodium Chloride Injection recall (Fresenius Kabi USA, LLC)
DrugClass IIReported April 15, 2026 · Lack of Assurance of Sterility - Lanreotide Injection recall (Cipla USA, Inc.)
DrugClass IIReported April 15, 2026 · Lack of Assurance of Sterility: Due to an FDA observation at the contract manufacturing site for deficiencies in their visual inspection procedure. - Lanreotide Injection recall (Cipla USA, Inc.)
DrugClass IIReported April 15, 2026 · Lack of Assurance of Sterility: Due to an FDA observation at the contract manufacturing site for deficiencies in their visual inspection procedure. - Magnesium Sulfate in Water for Injection recall (Amneal Pharmaceuticals, LLC)
DrugClass IReported April 8, 2026 · Product mix up: a foil pouch labeled "Magnesium Sulfate in Water for Injection, 4 g/100 mL" actually contained an IV bag of Tranexamic Acid instead. - Prazosin Hydrochloride Capsules recall (Appco Pharma LLC)
DrugClass IIReported April 8, 2026 · cGMP deviation: detection of Nitrosamine Drug Substance-Related Impurities, N-nitroso-prazosin impurity C (NNP) above acceptable limits. - Prazosin Hydrochloride Capsules recall (Appco Pharma LLC)
DrugClass IIReported April 8, 2026 · cGMP deviation: detection of Nitrosamine Drug Substance-Related Impurities, N-nitroso-prazosin impurity C (NNP) above acceptable limits. - Prazosin Hydrochloride Capsules recall (Appco Pharma LLC)
DrugClass IIReported April 8, 2026 · cGMP deviation: detection of Nitrosamine Drug Substance-Related Impurities, N-nitroso-prazosin impurity C (NNP) above acceptable limits. - Artificial Tears Sterile Lubricant Eye Drops recall (K.C. Pharmaceuticals, Inc)
DrugClass IIReported April 8, 2026 · Lack of Assurance of Sterility - STERILE EYE DROPS SOOTHING TEARS recall (K.C. Pharmaceuticals, Inc)
DrugClass IIReported April 8, 2026 · Lack of Assurance of Sterility - Sterile EYE DROPS REDNESS LUBRICANT recall (K.C. Pharmaceuticals, Inc)
DrugClass IIReported April 8, 2026 · Lack of Assurance of Sterility - Sterile Eye Drops ORIGINAL FORMULA recall (K.C. Pharmaceuticals, Inc)
DrugClass IIReported April 8, 2026 · Lack of Assurance of Sterility - Ultra Lubricating Eye Drops recall (K.C. Pharmaceuticals, Inc)
DrugClass IIReported April 8, 2026 · Lack of Assurance of Sterility - Dry Eye Relief Eye Drops recall (K.C. Pharmaceuticals, Inc)
DrugClass IIReported April 8, 2026 · Lack of Assurance of Sterility - EYE DROPS Advanced Relief recall (K.C. Pharmaceuticals, Inc)
DrugClass IIReported April 8, 2026 · Lack of Assurance of Sterility - Sterile EYE DROPS AC recall (K.C. Pharmaceuticals, Inc)
DrugClass IIReported April 8, 2026 · Lack of Assurance of Sterility - traMADol Hydrochloride Tablets recall (Amneal Pharmaceuticals, LLC)
DrugClass IIReported April 8, 2026 · Failed Impurities/Degradation Specifications: N-nitroso-desmethyl-tramadol impurity (NDSRI) was found out of the specification at 24-month stability interval... - Meclizine Hydrochloride Tablets recall (Amerisource Health Services LLC)
DrugClass IIReported April 1, 2026 · Failed tablet specifications. - Octreotide Acetate for Injectable Suspension recall (Teva Pharmaceuticals USA, Inc)
DrugClass IIReported April 1, 2026 · Lack of Assurance of Sterility: Quality system deficiencies identified during a routine U.S Food and Drug Administration (FDA) inspection at the contract... - Octreotide Acetate for Injectable Suspension recall (Teva Pharmaceuticals USA, Inc)
DrugClass IIReported April 1, 2026 · Lack of Assurance of Sterility: Quality system deficiencies identified during a routine U.S Food and Drug Administration (FDA) inspection at the contract... - Octreotide Acetate for Injectable Suspension recall (Teva Pharmaceuticals USA, Inc)
DrugClass IIReported April 1, 2026 · Lack of Assurance of Sterility: Quality system deficiencies identified during a routine U.S Food and Drug Administration (FDA) inspection at the contract... - Levothyroxine Sodium Tablets USP 150 mcg recall (MACLEODS PHARMA USA, INC)
DrugClass IIReported April 1, 2026 · Subpotent Drug - CUROSURF recall (Chiesi USA, Inc.)
DrugClass IIReported April 1, 2026 · Lack of Assurance of Sterility - Gelatin Capsule Pack for use with the Sodium Iodide I-131 Kit recall (Radnostix)
DrugClass IIIReported April 1, 2026 · Failed Tablet/Capsule Specifications - Webcol Alcohol Prep pad recall (Cardinal Health 200, LLC)
DrugClass IReported March 25, 2026 · Non-Sterility: microbial contamination identified as Paenibacillus phoenicis - Brimonidine Tartrate/Timolol Maleate Ophthalmic Solution 0.2%/0.5%* recall (Apotex Corp.)
DrugClass IIReported March 25, 2026 · Lack of Assurance of Sterility - Dexamethasone Sodium Phosphate Injection recall (SOMERSET THERAPEUTICS LLC)
DrugClass IIReported March 25, 2026 · Failed Impurities/Degradation Specifications - OOS impurities result observed during long term stability testing at product expiry (24 months) were above specs... - Pitavastatin Tablets recall (Annora Pharma Private Limited)
DrugClass IIIReported March 25, 2026 · Presence of foreign tablets/capsules: one Pitavastatin tablet 1mg found in bottle of Pitavastatin tablets 2mg - Children's Ibuprofen Oral Suspension recall (STRIDES PHARMA INC)
DrugClass IIReported March 25, 2026 · Presence of foreign substance: the firm received complaints for a gel-like mass and black particles in the product. - Icosapent Ethyl Capsules recall (Zydus Pharmaceuticals (USA) Inc)
DrugClass IIReported March 18, 2026 · Failed Tablet/Capsule specifications: Red dots inside capsule and melted capsule caused by oxidized Icosapent ethyl, the active ingredient. - Amnesteem recall (MYLAN PHARMACEUTICALS INC)
DrugClass IIReported March 11, 2026 · Failed Dissolution Specifications - MR. 7 SUPER 700000 capsules recall (StuffbyNainax)
DrugClass IReported March 11, 2026 · Marketed Without an Approved NDA/ANDA: FDA analysis revealed the presence of undeclared sildenafil and tadalafil - Tirzepatide Inj recall (New Life Pharma LLC)
DrugClass IIReported March 11, 2026 · Lack of Assurance of Sterility - Tirzepatide Inj recall (New Life Pharma LLC)
DrugClass IIReported March 11, 2026 · Lack of Assurance of Sterility - Semaglutide Inj. recall (New Life Pharma LLC)
DrugClass IIReported March 11, 2026 · Lack of Assurance of Sterility - Semaglutide Inj recall (New Life Pharma LLC)
DrugClass IIReported March 11, 2026 · Lack of Assurance of Sterility - Sodium Iodide recall (Radnostix)
DrugClass IIReported March 11, 2026 · Presence of Particulate Matter: Due to production issues - MAXIMUM recall (HTO Nevada Inc. dba Kirkman)
DrugClass IIReported March 11, 2026 · Stability Data Does Not Support Expiry Date. - MAXIMUM recall (HTO Nevada Inc. dba Kirkman)
DrugClass IIReported March 11, 2026 · Stability Data Does Not Support Expiry Date. - FIVE-STAR recall (HTO Nevada Inc. dba Kirkman)
DrugClass IIReported March 11, 2026 · Stability Data Does Not Support Expiry Date. - Product label: Temozolomide Capsules recall (Rising Pharma Holding, Inc.)
DrugClass IIReported March 11, 2026 · Failed Impurities/Degradation Specifications: An out-of-specification result observed during 9th-month long term stability testing - Midodrine Hydrochloride Tablets recall (The Harvard Drug Group LLC)
DrugClass IIReported March 11, 2026 · Defective container; inadequately sealed blister packaging. - Nilotinib Capsules recall (Cipla USA, Inc.)
DrugClass IIIReported March 11, 2026 · Failed Tablet/Capsule Specifications: Observed OOS results at 6-months long-term stability condition for Description test and Appearance by Visual Inspection... - Nilotinib Capsules recall (Cipla USA, Inc.)
DrugClass IIIReported March 11, 2026 · Failed Tablet/Capsule Specifications: Observed OOS results at 6-months long-term stability condition for Description test and Appearance by Visual Inspection... - Semaglutide recall (Harbin Jixianglong Biotech Co., Ltd.)
DrugClass IIReported March 11, 2026 · CGMP Deviations This recall has been initiated due to failing to complete process validation and bacterial endotoxin method validation before distribution - Semaglutide recall (Harbin Jixianglong Biotech Co., Ltd.)
DrugClass IIReported March 11, 2026 · CGMP Deviations This recall has been initiated due to failing to complete process validation and bacterial endotoxin method validation before distribution - Antimicrobial Alcohol Hand Wipe recall (ACME UNITED CORPORATION)
DrugClass IIReported March 11, 2026 · CGMP Deviations